China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294

Watchlist Manager
China Resources Boya Bio pharmaceutical Group Co Ltd Logo
China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
Watchlist
Price: 30.96 CNY 0.23%
Market Cap: 15.6B CNY
Have any thoughts about
China Resources Boya Bio pharmaceutical Group Co Ltd?
Write Note

China Resources Boya Bio pharmaceutical Group Co Ltd
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

China Resources Boya Bio pharmaceutical Group Co Ltd
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
China Resources Boya Bio pharmaceutical Group Co Ltd
SZSE:300294
Long-Term Investments
ÂĄ194.9m
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
11%
Beigene Ltd
HKEX:6160
Long-Term Investments
ÂĄ635.2m
CAGR 3-Years
25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Long-Term Investments
ÂĄ10m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Long-Term Investments
ÂĄ1.4B
CAGR 3-Years
89%
CAGR 5-Years
126%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Long-Term Investments
ÂĄ17B
CAGR 3-Years
8%
CAGR 5-Years
117%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Long-Term Investments
ÂĄ295.2m
CAGR 3-Years
6%
CAGR 5-Years
24%
CAGR 10-Years
39%
No Stocks Found

China Resources Boya Bio pharmaceutical Group Co Ltd
Glance View

Market Cap
15.6B CNY
Industry
Biotechnology

Boya Bio-pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of blood products. The company is headquartered in Fuzhou, Jiangxi and currently employs 1,652 full-time employees. The company went IPO on 2012-03-08. The firm's main products include human albumin, freeze-drying intravenous injection human immune globulin, human immune globulin, hepatitis B human immune globulin, hydrophobia human immune globulin, human fibrinogen, metformin hydrochloride, calcium dobesilate capsules, glimepiride and pioglitazone hydrochloride dispersible tablets, among others. The firm's blood products are mainly used in the treatment of tumor, liver diseases and diabetes, among others. The firm also provides diabetic pharmaceuticals and biochemical pharmaceuticals. The firm distributes its products mainly in domestic market.

Intrinsic Value
32.53 CNY
Undervaluation 5%
Intrinsic Value
Price

See Also

What is China Resources Boya Bio pharmaceutical Group Co Ltd's Long-Term Investments?
Long-Term Investments
194.9m CNY

Based on the financial report for Sep 30, 2024, China Resources Boya Bio pharmaceutical Group Co Ltd's Long-Term Investments amounts to 194.9m CNY.

What is China Resources Boya Bio pharmaceutical Group Co Ltd's Long-Term Investments growth rate?
Long-Term Investments CAGR 10Y
11%

Over the last year, the Long-Term Investments growth was 73%. The average annual Long-Term Investments growth rates for China Resources Boya Bio pharmaceutical Group Co Ltd have been 10% over the past three years , 7% over the past five years , and 11% over the past ten years .

Back to Top